The US Food and Drug Administration (FDA) has granted orphan drug designation to MB-105, March Biosciences’ CD5-targeted CAR-T cell therapy for the treatment of relapsed/refractory CD5-positive T-cell lymphoma (TCL).  MB-105 is in development as a treatment for TCL, T-cell acute lymphoblastic leukaemia (T-ALL), chronic lymphocytic leukaemia (CLL), and mantle cell lymphoma (MCL).  It is currently […]